SequelSEC

BIOFORCE NANOSCIENCES HOLDINGS, INC. BFNH

Laboratory Analytical Instruments · CIK 0001310488 · Fiscal year ends 1231

Revenue
$17.77K
Fiscal year ended 2019-12-31
Operating income
-$46.54K
Fiscal year ended 2019-12-31
Free cash flow
Unavailable
Fiscal year ended 2019-12-31

Valuation, from the filing

Public float$2.63MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.08Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Laboratory Analytical Instruments filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin24.5%0th
Net margin-261.8%18th
Revenue YoY growth9.0%82th
Current ratio5.08x65th

BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) reported revenue of $17.77K and net income of -$46.54K for the fiscal year ended 2019-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BIOFORCE NANOSCIENCES HOLDINGS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.

Income

BIOFORCE NANOSCIENCES HOLDINGS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-31
Revenue$17.77K
Cost of revenue$13.42K
Gross profit$4.36K
Operating income-$46.54K
Net income-$46.54K
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$46.54K
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$50.90K
Selling & marketingUnavailable

Balance

BIOFORCE NANOSCIENCES HOLDINGS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-31
Cash & equivalents$52.90K
Total assets$58.90K
Current assets$58.90K
Total liabilities$11.59K
Current liabilities$11.59K
Total equity incl. NCI$47.31K
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

BIOFORCE NANOSCIENCES HOLDINGS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-31
Operating cash flow-$24.38K
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$47.89K
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

BIOFORCE NANOSCIENCES HOLDINGS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-31
Free cash flowUnavailable
Gross margin24.5%
Operating margin-261.8%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio5.08x
Revenue YoY growthUnavailable
Net margin-261.8%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BFNH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-19View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.